Oral News and Research

RSS

Pfizer’s Revatio Injection receives FDA approval

Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.

20 Nov 2009

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex® Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.

20 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

Quest Diagnostics reports sharp downward trends in cocaine and methamphetamine use

New data released today by Quest Diagnostics Incorporated, the nation's leading provider of employment-related drug testing services, reveal that drug testing of hair specimens from employees and job applicants in the general U.S. workforce has tracked sharp downward trends in cocaine and methamphetamine use from 2005 to the first half of 2009 that mirror similar drops shown by urine testing.

From Quest Diagnostics 20 Nov 2009

Precision BioSciences: EPO revokes Cellectis’ European Patent No. EP 1485475

Yesterday, the European Patent Office (EPO) revoked previously granted claims of Cellectis’ European Patent No. EP 1485475 during an oral hearing in an opposition proceeding initiated by Precision BioSciences. As a result of the opposition, Cellectis’ previously granted claims to single-chain meganucleases, including those derived from I-CreI, were revoked in their entirety. Claims to hybrid meganucleases were cancelled or severely restricted.

19 Nov 2009

BioAlliance Pharma wins first prize in Deloitte's Technology Fast 50 2009

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it has won first prize in Deloitte's Technology Fast 50 2009TM ranking of France's fastest-growth technology companies.

19 Nov 2009

Nicardipine Hydrochloride Injection for short-term treatment of hypertension launched

Caraco Pharmaceutical Laboratories, Ltd. has launched Nicardipine Hydrochloride Injection immediately following Sun Pharma's final approval from the US Food and Drug Administration (FDA).

19 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients.

18 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

Chembio Diagnostics to present possibilities of OTC home-use HIV test kits at the FDA meeting

Chembio Diagnostics, Inc., a company that develops, manufactures, licenses, and markets proprietary rapid diagnostic tests, announced today that it will present at a meeting of the Blood Products Advisory Committee ("BPAC") of the U.S. Food and Drug Administration ("FDA") in Bethesda, Maryland, on the afternoon of November 17, 2009.

18 Nov 2009

Study examines link between folic acid and cancer incidence

Patients with heart disease in Norway, a country with no fortification of foods with folic acid, had an associated increased risk of cancer and death from any cause if they had received treatment with folic acid and vitamin B12, according to a study in the November 18 issue of JAMA.

18 Nov 2009

Review of the results of Phase 2b clinical trial on PASCAL announced

ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

18 Nov 2009

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. But a revolutionary new wound dressing developed at Tel Aviv University could cut that number dramatically.

18 Nov 2009

Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design and delivery, has announced an exclusive Development and Commercial License Agreement for the company’s AppiForm™ Modular Release System with Capsugel, the world's leading provider of dosage form solutions to the pharmaceutical and related healthcare industries. The agreement provides for Capsugel to utilize the AppiForm Modular Release System for customizable drug delivery profiles.

17 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

Cytokinetics, Incorporated announced today that three abstracts summarizing non-clinical data regarding its smooth muscle contractility program were presented at the 2009 Scientific Sessions of the American Heart Association in Orlando, Florida.

17 Nov 2009

IntelGenx completes first successful human study of an anti-migraine film

IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

LEAD Therapeutics discovers orally available PARP inhibitor

LEAD Therapeutics, a privately held drug discovery company, today announced the discovery of a novel, orally available, PARP inhibitor with potent anti-tumor activity both as single-agent treatment and in combination with chemotherapy drugs.

17 Nov 2009

Oral News and Research

Pfizer’s Revatio Injection receives FDA approval

Boston Scientific's WallFlex Fully Covered Esophageal Stent receives FDA clearance and CE Mark approval

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Quest Diagnostics reports sharp downward trends in cocaine and methamphetamine use

Precision BioSciences: EPO revokes Cellectis’ European Patent No. EP 1485475

BioAlliance Pharma wins first prize in Deloitte's Technology Fast 50 2009

Nicardipine Hydrochloride Injection for short-term treatment of hypertension launched

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Chembio Diagnostics to present possibilities of OTC home-use HIV test kits at the FDA meeting

Study examines link between folic acid and cancer incidence

Review of the results of Phase 2b clinical trial on PASCAL announced

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Capsugel to have exclusive rights to Appian Labs' AppiForm Modular Release System technology

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

IntelGenx completes first successful human study of an anti-migraine film

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

LEAD Therapeutics discovers orally available PARP inhibitor

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News